Table 2. Dapagliflozin treatment improves T1DM-induced metabolic changes.
| Metabolic parameters | Control (C) | Diabetic (D) | D+DAPA |
|---|---|---|---|
| Body weight (g) | 442±35.4 | 256±29.9*** | 340±35.0§§ |
| Non-fasting glucose (mmol/L) | 6.42±0.58 | 33.3±1.06*** | 16.2±5.29***§§§ |
| Fructosamine (μmol/L) | 143±3.74 | 277±12.3*** | 198±34.9§§§ |
| Total cholesterol (mmol/L) | 1.96±0.15 | 2.82±0.30*** | 1.89±0.40§§§ |
| Triglycerides (mmol/L) | 1.24±0.51 | 3.12±1.17** | 1.00±0.51§§§ |
| LDL-C (mmol/L) | 0.44±0.15 | 0.84±0.11*** | 0.48±0.13§§§ |
| GOT (U/L) | 127±19.6 | 382±164*** | 187±24.1§§ |
| GPT (U/L) | 43.0±8.39 | 181±82.1*** | 80.1±16.1§§ |
| Glucosuria | UN | 346±47.1*** | 491±94.2***§§ |
C, Control; D, diabetic; D+DAPA, dapagliflozin-treated diabetic; LDL-C, low-density lipoprotein cholesterol; GOT, serum glutamate-oxaloacetate transaminase; GPT, serum glutamate-pyruvate transaminase; p values indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n = 6 /group).
**p<0.01 vs. Control
***p<0.001 vs. Control
§§p<0.01 vs. Diabetic
§§§p<0.001 vs. Diabetic UN: undetectable.